Jonathan Pollack

Administrative Appointments

• Founding Director, Stanford Tissue Bank (2001 - 2010)

Honors and Awards

• Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund (2008)
• Elected member, American Society for Clinical Investigation (2006)
• Amgen Outstanding Investigator Award, American Society of Investigative Pathology (2006)

Professional Education

Postdoctoral Advisees

Ilona Holcomb

Graduate & Fellowship Program Affiliations

• Cancer Biology

Internet Links

• http://pollacklab.stanford.edu
• Pollack Lab Home Page

Current Research Interests

Our laboratory uses genomic approaches to investigate the pathogenesis and biology of human cancer, and to identify strategies for improved cancer diagnosis, prognostication and patient management. Technologies include DNA microarrays, deep sequencing, and shRNA screens, and additional insight is provided by the biocomputational integration of different data types.

Active areas of investigation include: (1) Characterizing molecular subtypes of prostate cancer to identify biomarkers for risk-assessment; (2) Identifying recurrent DNA copy number alterations and rearrangements in common epithelial tumor types (e.g. breast, prostate, lung, colon, and pancreatic cancers) to discover new cancer genes; (3) Understanding the role of newly-discovered "lineage-dependent" oncogenes in tumorigenesis; and (4) Investigating mechanisms underlying genomic instability and the shaping of cancer genomes.

Clinical Trials

• Biopsy of human tumors for cancer stem cell characterization: a feasibility study Recruiting
• Microarray Analysis of Gene Expression in Prostate Tissues Recruiting
• Evaluation of Pathwork Tissue of Origin (TOO) test for human malignancies Completed

Publications

• Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A, Pollack JR. Proc Natl Acad Sci U S A. 2012
• A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. Malhotra S, Lapointe J, Salari K, Higgins JP, Ferrari M, Montgomery K, van de Rijn M, Brooks JD, Pollack JR. PLoS One. 2011; 6 (5): e20293
• Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR. Oncogene. 2011
• SMURF1 amplification promotes invasiveness in pancreatic cancer. Kwei KA, Shain AH, Bair R, Montgomery K, Karikari CA, van de Rijn M, Hidalgo M, Maitra A, Bashyam MD, Pollack JR. PLoS One. 2011; 6 (8): e23924
• DR-Integrator: a new analytic tool for integrating DNA copy number and gene expression data. Salari K, Tibshirani R, Pollack JR. Bioinformatics. 2010; 26 (3): 414-6